Federal regulation of the advertising and promotion of pharmaceuticals and medical devices reflects an aggressive attitude on the part of the regulators that demands, in turn, that industry be keenly aware of the legal and regulatory duties, as well as key recent trends in enforcement activities by the Federal Government. This course will explore in detail what FDA requires of drug and device firms as well as recent current hot buttons in FDA enforcement activity for the advertising arena.

What’s at stake if your advertising and promotional efforts violate the law? Colossal fines – the latest was $3 Billion; criminal liability, including even prison time; and huge disruption in operations while dealing with federal probes into illegal marketing.

Learning Objectives:-

Key goals of the conference will include learning:

• The basics of FDA law and regulations governing advertising and promotion, as well as sister agencies such as the Federal Trade Commission, which shares jurisdiction with FDA on certain regulated products (e.g., OTC drugs).
• The distinctions between labels, labeling, and advertising and how that impacts the FDA's powers, and
• How to properly position Direct-to-Consumer (DTC) promotions
• The Dos and Don'ts of promoting products on the internet, including social media sites such as Facebook and Twitter
• The perils of off-label promotion, including criminal and civil actions that have led to multi-billion dollar settlements by regulated drug companies
• Whether the First Amendment provides any insulation for truthful statements regarding regulated products;
• When disseminating medical educational materials crosses the line into improper promotion; and
• Key considerations on how to implement appropriate procedures and controls in your company to minimize the potential for regulatory action by the FDA or the FTC relative to promotion and advertising.

Agenda:-

Day 01 (Thursday, March 19, 2020, 09:00 AM EST - 05:00 PM EST)

• Understanding the Basics
  • Who Has Jurisdiction
    • Drugs & Biologics
      • Rx Drug Advertising
      • OTC Drug Advertising
    • Devices
      • Restricted
      • all other
  • Labeling vs. Advertising
  • Basic drug rules
    • Fair balance
  • Device rules
    • Intended use deviations
  • DTC advertising
    • Print
    • TV
  • Comparative Claims
    • standard to support
    • push to pursue CER
  • Detailing and Sampling
    • is there still a future?
    • what can be said?
    • the danger of “custom” pieces
  • How FDA learns of violations
    • Keep your house clean or your competitors will rat you out
• II. Scientific Exchange
  • Guidances on Dissemination of Scientific Information
  • Risks involved in Off-Label Statements
  • Procedural Requirements and Unsolicited Requests for Information
• III. First Amendment
  • Understanding “Commercial Speech” Doctrine
  • FDA and the Regulation of Advertising
• IV. Websites & Social Media
  • FDA Policies on the Internet
  • Recent FDA Enforcement Activities
  • How to Handle at the Company Levels

Day 02 (Friday, March 20, 2020, 09:00 AM EST - 05:00 PM EST)

• Enforcement Trends
  • FDA Hot Buttons
    • Understating risk
    • Overstating effectiveness
  • FTC
    • POM Wonderful and substantiation
  • Private Litigation – Understanding
    • Lanham Act
    • State Unfair Competition
• VI. False Claims Act and Criminal Liability
  • Review of Key Settlements
  • “Responsible Corporate Official” Liability
• VII. Handling at the Company Level
  • Compliance Programs
  • Internal processes

Who Will Benefit?

Senior executives, directors, managers and those who have responsibility for implementing advertising and promotional activities, as well as those that have key collateral roles in reviewing advertising for drug and device firms, including officials from these areas within regulated companies:

• Sales
• Marketing
• Medical Affairs
• Legal
• Regulatory
• Compliance